Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current management strategies for hypercalcemia.

Martin Pecherstorfer1, Karin Brenner, Niklas Zojer

  • 1First Department of Medicine and Medical Oncology, Wilhelminenspital, Vienna, Austria. Martin.Pecherstorfer@1me.wil.magwien.gv.at

Treatments in Endocrinology
|June 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychometric properties of the ICECAP-SCM capability-wellbeing measure in specialist palliative care units in Austria.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2025
Same author

Real-world evidence of imatinib treatment in younger and older patients with chronic myeloid leukaemia: A retrospective single centre analysis.

Oncology letters·2025
Same author

Real-World Data on the Efficacy of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma and Amplification 1q.

Cancers·2025
Same author

Palliative Radiotherapy Near the End of Life: An Analysis of Factors Influencing the Administration of Radiotherapy in Advanced Tumor Disease.

JCO global oncology·2025
Same author

Treatment of stage IV colorectal cancer: A retrospective cohort study assessing whether failure of first‑line treatment indicates failure of second‑line treatment.

Molecular and clinical oncology·2024
Same author

QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 study.

EJHaem·2024

Hypercalcemia, often caused by primary hyperparathyroidism or cancer, is managed with bisphosphonates. Nitrogen-containing bisphosphonates like zoledronate show greater efficacy and longer response durations than older agents.

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • Hypercalcemia commonly results from primary hyperparathyroidism or malignancy.
  • Primary hyperparathyroidism is curable with parathyroidectomy; pharmacological treatment is for symptomatic cases.
  • Malignant hypercalcemia requires prompt treatment to prevent severe complications.

Purpose of the Study:

  • To review current pharmacological treatments for hypercalcemia.
  • To compare the efficacy and safety of various bisphosphonates in managing hypercalcemia of malignancy.

Main Methods:

  • Literature review of pharmacological interventions for hypercalcemia.
  • Analysis of bisphosphonate efficacy, focusing on nitrogen-containing agents.
  • Comparison of adverse event profiles and response durations.

Related Experiment Videos

Main Results:

  • Bisphosphonates are mainstays for hypercalcemia of malignancy; nitrogen-containing bisphosphonates (e.g., zoledronate, pamidronate) are more potent.
  • Zoledronate demonstrated superior efficacy and longer duration of response compared to pamidronate in a recent study.
  • Adverse events primarily involve renal function and transient flu-like symptoms; hypocalcemia can occur.

Conclusions:

  • Bisphosphonates, particularly nitrogen-containing ones, are effective for hypercalcemia of malignancy.
  • Zoledronate shows promise for improved outcomes in malignant hypercalcemia.
  • Other agents like calcitonin and gallium nitrate have roles in specific scenarios or require further investigation.